Stryker touts pivotal study for SpineJack vertebral fracture device
Stryker (NYSE:SYK) last week touted positive results from its SpineJack System study.
The SpineJack System was tested against balloon kyphoplasty (BKP) in the treatment of painful osteoporotic vertebral compression factors. Results showed that the system had non-inferiority to BKP and had an excellent risk/benefit profile for up to 12 months, according to the company.
Stryker’s SpineJack System allows physicians to customize vertebral compression fracture treatment approaches for individual patients. The system gives physicians the ability to take control of the procedure and restore the anatomy while reducing the possibility of future adjacent level fractures.
SpineJack titanium implants are inserted and expanded into fractured vertebrae through small incisions. PMMA bone cement is then injected at low pressure to stabilize the restored vertebral body.